Psych Congress 2026: Program & Speakers
60 major sessions across 5 days with 71 confirmed speakers — the substantive program for Psych Congress 2026, September 15–19, 2026 in New Orleans, LA. Curated from the official program; excludes posters, exhibits, and social events.
Featured speakers: Brittany Albright · Rakesh Jain · Gregory Mattingly · David Plante · James Greenblatt · Ashley Mason · Charles Raison · Marcus Capone · Amber Capone · Matthew Zorn · Saundra Jain · Andrew Penn · and 59 more below
No sessions match those filters. — or browse the full official program.
September 15, 2026
- CourseAdvanced Psychopharmacology Intensive: Emerging Neurobiologic Targets and Metabolic Pathways Reshaping Psychiatric Treatment
Brittany Albright · Rakesh Jain · Gregory Mattingly · David Plante
Half-day ticketed intensive built around four expert-led modules on treatment mechanisms moving beyond monoamines: orexin-based agents, glutamate/dopamine circuit approaches, muscarinic receptor modulation, and GLP-1/bioenergetic pathways.
GLP-1 & Metabolic PsychiatryMuscarinic & Novel AntipsychoticsNeuroscience & MechanismsDrug Pipeline & Clinical Trials
- CourseIntegrative PsychiatryIntegrative Psychiatry Intensive: Systems-Level Biology and Lifestyle Factors Transforming Psychiatric Practice
James Greenblatt · Ashley Mason · Charles Raison
Half-day ticketed intensive covering four integrative domains — temperature-based interventions, rapid sleep-optimization strategies, nutritional psychiatry, and metabolic regulation of brain function — framed as complements to standard psychopharmacology.
GLP-1 & Metabolic PsychiatryLifestyle & Integrative PsychiatrySleep & Insomnia
- DebatePsychedelicsPsychedelic Therapy After the Executive Order: Now What?
Marcus Capone · Amber Capone · Matthew Zorn · Rakesh Jain · Saundra Jain · Andrew Penn · Charles Raison
Opening-afternoon multidisciplinary panel pairing a patient's lived-experience story with a policy update on how the recent executive order and existing regulatory frameworks may shape near-term clinical use of psychedelic therapies.
- LectureDifficult MedicinesDifficult Medicines: The Art and Science of Lithium Therapy
Practical deep dive on lithium's mechanisms and dosing precision, including monitoring, toxicity mitigation, adherence, and use in special populations.
- SymposiumPediatric PsychiatryRethinking Pediatric Depression: Early Identification and Emerging Treatments
Adelaide S. Robb · Julie Carbray · Liv Lewis
Reviews atypical presentations of youth depression and newer options including rapid-acting agents and digital therapeutics, with strategies for early detection in schools and primary care and a lived-experience perspective.
- SymposiumIntegrative PsychiatrySmall Changes, Big Impact: How to Bring Lifestyle and Nutritional Psychiatry into Real-World Practice
Mariela Podolski · James Somers
Workflow-friendly tactics for weaving sleep, exercise, stress management, social connection, and nutritional assessment into time-limited medication visits.
- SymposiumMasterClassMasterClass: Seeing the Bigger Picture: How to Evaluate Real-World Evidence Along with RCTs in Psychiatric Treatment Decisions
Teaches clinicians to weigh real-world study designs against randomized trials, including examples where RWE informed FDA-approved psychiatric therapies.
- SymposiumMasterClassMasterClass: Presynaptic Possibilities: The Past, Present, and Future of Modulating Dopamine
Christoph U. Correll · Chelsie Monroe
Covers presynaptic dopamine modulation in schizophrenia and bipolar I mania, including evidence for selective muscarinic agents and how to apply them to individual patients.
Bipolar DisorderMuscarinic & Novel AntipsychoticsSchizophrenia & Psychosis
- SymposiumMasterClassMasterClass: Could Glutamatergic Modulation be the Keystone of Durable Change in Treatment-Resistant Depression?
Brittany Albright · Michael Asbach
Examines glutamatergic dysfunction in MDD and the evidence for current and emerging glutamate-targeting therapies in treatment-resistant depression.
Ketamine & EsketamineNeuroscience & MechanismsTreatment-Resistant Depression
- SymposiumSubstance Use DisordersCannabis Use and Mental Illness: What We Now Know (and Don't)
Updates clinicians on cannabis-induced psychosis, mood effects, and dose-response data amid rising THC potency, with practical tapering strategies and treatment pathways for cannabis use disorder.
Cannabis & CannabinoidsSchizophrenia & PsychosisSubstance Use Disorders
- SymposiumSolving Clinical ChallengesSolving Clinical Challenges: Managing Major Depressive Disorder When First-Line Treatments Fall Short
Brittany Albright · Rebecca Barbee · Kristian Dambrino
Case-based walkthrough of evaluating apparent treatment resistance in MDD — uncovering hidden contributors like anxiety, trauma, and medical illness — and choosing among optimization, augmentation, and switching pathways.
- LectureForensic PsychiatryWhen Symptoms Are Questioned: Assessing Malingering and Factitious Disorders
Forensic session on distinguishing genuine psychiatric illness from feigned or exaggerated presentations, covering interviewing tools, documentation, ethics, and risk mitigation.
September 16, 2026
- LectureADHDADHD With Comorbidities: Anxiety, Mood Disorders, Autism, and Substance Use Disorders
Frameworks for diagnostic clarification and treatment sequencing when ADHD co-occurs with anxiety, mood disorders, autism, or substance use, balancing symptom control against misuse and destabilization risks.
ADHDAnxiety DisordersAutism & Neurodevelopmental DisordersSubstance Use Disorders
- SymposiumBorderline Personality DisorderBorderline Personality Disorder: Yes There is Treatment That Works!
Richard Jackson · Saundra Jain
Practical approach to early identification, risk evaluation, and DBT-informed skills for BPD in brief outpatient visits, including when adjunctive pharmacotherapy is warranted.
- LectureBipolar DisordersComplex Psychopharmacology in Bipolar Disorder: Combination Therapy, Dosing Pearls & Side-Effect Navigation
Advanced guidance on sequencing lithium, anticonvulsants, and atypical antipsychotics in bipolar disorder, with case vignettes on inadequate response, intolerability, and polypharmacy.
Antipsychotic PrescribingBipolar DisorderDeprescribing & PolypharmacyLithium & Mood Stabilizers
- SymposiumMasterClassMasterClass: AIMS Is Nothing but a Number: Focusing on Function and Family in Tardive Dyskinesia
Reframes tardive dyskinesia care around function and quality of life rather than rating scales alone, reviewing recognition, differential diagnosis, and VMAT2 inhibitor evidence.
- SymposiumMasterClassMasterClass: The Sleep-Psych Nexus: Understanding and Assessing Sleep Disturbances in Psychiatric Practice
Craig Chepke · Philip Gehrman · Logan Schneider
Explores the shared neurobiology of sleep and psychiatric illness with screening, diagnostic, and management strategies for complex sleep-wake disorders.
- SymposiumMasterClassMasterClass: Across Mood Episodes and Throughout the Lifespan: Atypical Antipsychotic Strategies for MDD and Bipolar Disorder
Gregory Mattingly · Desiree Matthews
Case-driven review of selecting atypical antipsychotics across mood episodes, weighing efficacy, tolerability, adherence, and patient-specific factors.
- SymposiumPsychotic DisordersNot All Delusions are Schizophrenia: Understanding Delusional Disorders and the Overlap with Substance Induced Psychosis
Uses a historic case to teach differential diagnosis of psychosis beyond schizophrenia — substance-induced, delusional, and medical causes — including temporal analysis, labs, and imaging.
Measurement-Based Care & DiagnosisSchizophrenia & PsychosisSubstance Use Disorders
- SymposiumBipolar DisordersDeprescribing Definitions and Decisions Differ by Diagnosis: A Deep Dive for Bipolar & Schizophrenia Disorders
Joseph Goldberg · Peter Weiden
Compares how polypharmacy patterns and risk-benefit calculations shape deprescribing decisions differently in bipolar disorder versus schizophrenia.
Bipolar DisorderDeprescribing & PolypharmacySchizophrenia & Psychosis
- SymposiumSRSF Partner SessionSolving Clinical Challenges: Untangling Sleep Problems in Psychiatric Practice
Philip Gehrman · Rakesh Jain · Hara E. Oyedeji
Case-based session on sorting whether insomnia or hypersomnia reflects medication effects, primary sleep disorders, circadian disruption, or worsening psychiatric illness, and when to order sleep studies. Developed with the Sleep Research Society Foundation.
- SymposiumFirst-Line DecisionsFirst-Line Decisions: Lifestyle Modification or Medication? Balancing Pharmacologic and Non-Pharmacologic Care in ADHD
James Greenblatt · Julie Carbray
Guides initial ADHD treatment choices between stimulant/non-stimulant medication and behavioral, coaching, and environmental strategies based on severity, preference, and comorbidity.
ADHDLifestyle & Integrative PsychiatryStimulants & ADHD Medications
- SymposiumMasterClassMasterClass: The Road to Recovery in MDD: From Partial Response to Remission and Beyond
Christoph U. Correll · Brooke Kempf
Focuses on recognizing clinically meaningful residual depressive symptoms and using adjunctive pharmacologic options to push partial responders toward remission and sustained recovery.
- SymposiumMasterClassMasterClass: Features Out of Focus: Recognition and Treatment of Emotional Dysregulation and Executive Dysfunction in ADHD
Gregory Mattingly · Julie Carbray
Highlights emotional dysregulation and executive dysfunction as underrecognized drivers of ADHD impairment, with neurobiological context and emerging pharmacologic options.
- SymposiumMasterClassMasterClass: Trouble Beneath the Surface: Detecting and Treating Hypersomnolence in Everyday Psychiatric Practice
Covers recognition and differential diagnosis of hypersomnolence disorders in psychiatric patients, plus diagnostic workup, referral, and current and emerging treatments.
- SymposiumAFSP Partner SessionSuicide Prevention in Psychiatric Practice: A Logical, Evidence-Based Framework
Jill Harkavy-Friedman · Cory Weissman
Reviews treatments with demonstrated anti-suicidal benefit — lithium, clozapine, ECT, and CBT-based approaches — within a structured framework for individualized prevention planning. Developed with the American Foundation for Suicide Prevention.
ClozapineLithium & Mood StabilizersNeuromodulation (ECT, TMS)Suicide & Self-Harm
- SymposiumAAGP Partner SessionThe Evolving Alzheimer's Landscape: Modern Approaches to Diagnosis and Treatment
Addresses early identification of Alzheimer's disease, responsible use of biomarkers and advanced diagnostics, and longitudinal pharmacologic and nonpharmacologic management. Developed with the American Association for Geriatric Psychiatry.
Dementia & Cognitive DisordersGeriatricMeasurement-Based Care & Diagnosis
- LectureBipolar DisordersTreatment-Resistant Bipolar Depression: Sequencing, Switching & Advanced Strategies
Step-by-step algorithms for treatment-resistant bipolar depression — when to switch, augment, or combine — with evidence on newer agents such as lumateperone, cariprazine, and ketamine.
Antipsychotic PrescribingBipolar DisorderKetamine & Esketamine
- SymposiumLatest Discoveries & Emerging TrendsLatest Discoveries & Emerging Trends in Psychotic Disorders
Christoph U. Correll · Ilan Melnick
Fast-paced review of the year's most significant schizophrenia and psychosis research, with expert commentary and selected poster presenters sharing emerging data.
September 17, 2026
- SymposiumFirst-Line DecisionsFirst-Line Decisions: Lifestyle Modification or Medication? Guiding Initial Care in Generalized Anxiety Disorder
Manish Jha · Saundra Jain · Vanessa Joy Walker
Helps clinicians decide between pharmacotherapy and CBT, mindfulness, sleep, and exercise strategies at the outset of GAD treatment based on severity, comorbidity, trauma history, and preference.
Anxiety DisordersLifestyle & Integrative PsychiatryPsychotherapy
- SymposiumLatest Discoveries & Emerging TrendsLatest Discoveries & Emerging Trends in MDD
Year-in-review of depression research spanning neurobiology, trial results, and pharmacologic and non-pharmacologic innovation, with selected poster presenters showcasing new data.
DepressionNeuroscience & MechanismsDrug Pipeline & Clinical Trials
- SymposiumNeurodevelopmental DisordersPractical Management of Autism and Co-Occurring Psychiatric Conditions
Integrated framework for assessing and treating anxiety, ADHD, and mood disorders in autistic children, including evidence-based medication use, behavioral therapy, and family engagement.
ADHDAnxiety DisordersAutism & Neurodevelopmental DisordersChild & Adolescent
- SymposiumMasterClassMasterClass: Unlocking the Doors of Depression: Neuroplastic and Psychedelic Therapies in MDD
Examines glutamatergic and serotonergic neuroplasticity pathways and the evidence base for investigational psychedelic and psychedelic-assisted therapies in major depression.
- SymposiumMasterClassMasterClass: Translating Orexin Science Into Practice: Psychiatry's Role in Narcolepsy Care
Craig Chepke · Logan Schneider · Jessica Wright
Covers orexin-deficiency neurobiology, how to distinguish narcolepsy from psychiatric mimics, and the clinical implications of emerging orexin receptor agonists.
Neuroscience & MechanismsDrug Pipeline & Clinical TrialsSleep & Insomnia
- SymposiumMasterClassMasterClass: Volition Reignition: Achieving Patient Goals by Detecting and Addressing Anhedonia in MDD
Brittany Albright · Veronica Ridpath
Focuses on reward-system dysfunction in depression, practical assessment of anhedonia, and emerging therapies aimed at restoring motivation and meaningful recovery.
DepressionMeasurement-Based Care & DiagnosisNeuroscience & Mechanisms
- SymposiumAnxiety DisordersWhen Anxiety Persists: Evidence-Based Strategies and Novel Pharmacologic Options Beyond First-Line Treatment
Step-by-step framework for treatment-resistant anxiety after SSRI/SNRI failure, covering sequencing, psychotherapy integration, and off-label and emerging agents from gabapentinoids to glutamatergic and GABAergic options.
Anxiety DisordersDrug Pipeline & Clinical TrialsPsychotherapy
- SymposiumWomen's Mental HealthWomen, Hormones, and ADHD: What We Know, What We Don't, and What Clinicians Need to Understand
Gregory Mattingly · Moushumi Mukerji
Evidence-informed overview of how estrogen and progesterone shifts across the menstrual cycle, pregnancy, and perimenopause affect attention, mood, and stimulant response, with prescribing considerations amid research gaps.
ADHDPerinatal & Women's Mental HealthStimulants & ADHD Medications
- SymposiumSRSF Partner SessionWhen Trauma Disrupts Sleep: Practical Interventions for PTSD-Related Sleep Disorders
Philip Gehrman · William Sauvé
Integrated pharmacologic and psychotherapeutic framework for assessing and treating trauma-related insomnia and nightmares. Developed with the Sleep Research Society Foundation.
- LectureIntegrative PsychiatryFat Matters: Understanding How Cholesterol and Fatty Acids Shape Psychiatric Illness
Connects cholesterol and omega-3 fatty acid biology to mood disorders, psychosis, and cognition, translating lipid research into assessment strategies and adjunctive interventions.
Dementia & Cognitive DisordersLifestyle & Integrative PsychiatryNeuroscience & Mechanisms
- LectureDifficult MedicinesDifficult Medicines: Navigating the Complexities of Clozapine
Deep dive into clozapine for treatment-resistant schizophrenia — initiation, monitoring requirements, side-effect management, and adherence — grounded in real-world cases.
ClozapineDrug Interactions & SafetySchizophrenia & Psychosis
September 18, 2026
- SymposiumLatest Discoveries & Emerging TrendsLatest Discoveries & Emerging Trends in Neurodevelopmental Disorders
Gregory Mattingly · Kristin Sohl
Highlights the year's key research in ADHD and autism, from genetics and brain-network findings to behavioral interventions and digital therapeutics, with selected poster presenters.
ADHDAutism & Neurodevelopmental DisordersDigital Psychiatry & AINeuroscience & Mechanisms
- LectureTechnologyDigital Psychiatry 2.0: Integrating AI, Wearables, and Digital Therapeutics Into Everyday Clinical Practice
Shows how validated digital biomarkers, passive monitoring, and app-based interventions can be folded into routine psychiatric visits without disrupting workflow.
- SymposiumISRP Partner SessionPMDD and Cyclical Mood Disorders: From Diagnosis to Novel Treatments
Pallavi Khanna · Kristin Lasseter
Covers diagnostic criteria and symptom tracking for premenstrual dysphoric disorder, differentiation from MDD and anxiety, and emerging neurosteroid and hormonal treatments. Developed with the International Society of Reproductive Psychiatry.
Measurement-Based Care & DiagnosisNovel AntidepressantsPerinatal & Women's Mental Health
- SymposiumInterventional PsychiatryNeuromodulation for Depression: Matching the Right Treatment to the Right Patient
Four case scenarios guide selection among TMS, ECT, VNS, theta-burst, and accelerated protocols, comparing mechanisms, indications, and sequencing within overall treatment plans.
DepressionNeuromodulation (ECT, TMS)Treatment-Resistant Depression
- SymposiumMasterClassMasterClass: Operationalizing Adherence: A Practical Guide to LAI Integration in Schizophrenia Care
Megan Ehret · Jaden Todd · Emma Nelson · Ilan Melnick · Amber Hoberg · Kevin Williams
Compares available long-acting injectable antipsychotic formulations and offers patient-centered communication and logistics strategies for initiating, administering, and reintroducing LAIs.
Antipsychotic PrescribingLong-Acting InjectablesSchizophrenia & Psychosis
- SymposiumMasterClassMasterClass: GAD Care Reimagined: Current Best Practices and the Emerging Role of Psychedelics
Brittany Albright · Andrew Penn
Pairs a review of current GAD standards of care with the therapeutic rationale and emerging evidence for investigational psychedelic compounds in anxiety.
- DebateSolving Clinical ChallengesSolving Clinical Challenges: Curbside Solutions for Complex Substance Use Disorder Cases
Arwen Podesta · Veronica Ridpath · Lydia Bartholow
Case-based panel dissecting complex opioid, stimulant, and withdrawal scenarios — including where system failures and clinical errors led to poor outcomes — with harm-reduction takeaways.
Emergency & Acute PsychiatryOpioid Use DisorderSubstance Use Disorders
- SymposiumPsychedelicsPsychedelics in Psychiatry: Where the Evidence Stands Today and What Comes Next
Evidence-focused update on psychedelic-assisted therapy trials, regulatory developments, and safety considerations, emphasizing separation of validated data from public enthusiasm.
- SymposiumObsessive-Compulsive DisorderSeeing Beyond the Mirror: Understanding and Treating Body Dysmorphic Disorder in Psychiatric Practice
Holly Peek · Moushumi Mukerji · Vanessa Joy Walker
Practical framework for recognizing BDD, overcoming poor insight and reassurance-seeking, and applying SSRIs and CBT with exposure/response prevention, including management of cosmetic treatment-seeking.
Measurement-Based Care & DiagnosisOCD & Related DisordersPsychotherapy
- SymposiumAFSP Partner SessionSuicide Risk Reconsidered: Brain, Biology, and Digital Influence Factors Every Psychiatrist Should Know
Steven Chan · Tory A. Eisenlohr-Moul · Matthew Hoptman
Rapid-fire session on three evolving suicide-risk contributors — neuroscience-identified brain functionality, hormonal influences across the lifespan, and AI chatbots in patients' mental health decisions. Developed with the American Foundation for Suicide Prevention.
Digital Psychiatry & AINeuroscience & MechanismsPerinatal & Women's Mental HealthSuicide & Self-Harm
- SymposiumDifficult MedicinesDifficult Medicines: Understanding the Opioid Treatment Landscape for Safe and Effective Outcomes
Elizabeth Langmore-Avila · Arwen Podesta
Compares methadone, buprenorphine, and naltrexone for opioid use disorder, covering patient selection, titration, cardiac and overdose considerations, sedative co-prescribing, and transitions between agents.
Benzodiazepines & SedativesDrug Interactions & SafetyOpioid Use Disorder
- SymposiumMDDModern Psychopharmacology for MDD: Switching, Sequencing, and Augmentation Strategies for Partial Responders
Mark Zimmerman · Shelley Matthews
Advanced review of switching protocols, cross-tapering, and augmentation options — lithium, T3, atypicals, dextromethorphan/bupropion, vortioxetine — for patients with incomplete antidepressant response.
DepressionLithium & Mood StabilizersNovel AntidepressantsTreatment-Resistant Depression
September 19, 2026
- SymposiumAAGP Partner SessionPsychosis, Dementia, or Depression? Clarifying Cognitive Decline in Older Adults
Shilpa Srinivansan · Amber Hoberg
Structured differential-diagnosis approach for cognitive and behavioral change in older adults, incorporating blood-based biomarkers, neuroimaging, and longitudinal tracking while managing neuropsychiatric symptoms. Developed with the American Association for Geriatric Psychiatry.
Dementia & Cognitive DisordersGeriatricMeasurement-Based Care & DiagnosisSchizophrenia & Psychosis
- LectureMDDInflammatory and Immune-Driven Depression: CRP, Biomarkers, and Anti-Inflammatory Treatment Pathways
Reviews the inflammatory depression phenotype and CRP-guided antidepressant selection, plus anti-inflammatory, glutamatergic, microbiome, and lifestyle interventions targeting immune activity.
DepressionInflammation & ImmunopsychiatryLifestyle & Integrative PsychiatryPharmacogenomics & Precision Psychiatry
- SymposiumIntegrative PsychiatryMind & Metabolic Matters: Practical Guidance on Prescribing GLP-1s in Psychiatry
Brittany Albright · Jonathan M. Meyer
Clinic-ready framework for GLP-1 and dual-incretin use in psychiatric patients: selection, titration, adverse-effect management, and psychiatric considerations including eating disorder risk, mood monitoring, and craving implications.
Drug Interactions & SafetyEating DisordersGLP-1 & Metabolic Psychiatry
- SymposiumMasterClassMasterClass: Stepping Out of Mania's Shadow: Understanding the Nuances of Recognizing and Treating Bipolar I and II Disorder
Craig Chepke · Kristian Dambrino
Strategies for distinguishing bipolar I, bipolar II, and MDD, the clinical relevance of specifiers, and evolving treatments supporting shared decision-making.
- DebateSchizophreniaWhen Standard Treatment Isn't Enough: Complex Schizophrenia Cases and Clinical Decision-Making
Leslie Citrome · Erin Crown · Brooke Kempf
Panel works through challenging schizophrenia cases involving treatment resistance and functional decline, covering sequencing, clozapine timing, augmentation, and metabolic and sedation trade-offs.
Antipsychotic PrescribingClozapineGLP-1 & Metabolic PsychiatrySchizophrenia & Psychosis
- SymposiumFirst-Line DecisionsFirst-Line Decisions: Lifestyle Modification or Medication? Early Treatment Pathways for PTSD
Rakesh Jain · Desiree Matthews · Clark Sabo
Guides the choice between trauma-focused psychotherapies (CPT, Prolonged Exposure) and pharmacotherapy (SSRIs, SNRIs, prazosin) in early PTSD care, alongside sleep stabilization and grounding skills.
- SymposiumISRP Partner SessionPerinatal Psychiatry in Practice: Balancing Mother and Fetus in Pharmacotherapy
Evidence-based guidance on psychotropic use in pregnancy and lactation, including dosing, risk communication, and collaboration with obstetric providers. Developed with the International Society of Reproductive Psychiatry.
- PlenaryClosing SessionCultivating Clinical Wisdom in Deprescribing - Practical Considerations for Psychiatry
Rakesh Jain · Saundra Jain · Arwen Podesta · Charles Raison
Closing session on when and how to reduce psychotropic regimens: identifying candidates, shared decision-making, and safe tapering while weighing relapse and withdrawal risks.
Never miss an early-bird deadline
One-click alerts for this conference — we email you 14 and 3 days before each deadline:
Browse the directory
By date
By specialty
- General Psychiatry
- Psychopharmacology
- Child & Adolescent Psychiatry
- Addiction Psychiatry
- Geriatric Psychiatry
- Forensic Psychiatry
- Consultation-Liaison Psychiatry
- Anxiety & Depression
- Neuroscience
- Psychiatric Nursing / PMHNP
- ADHD
- Bipolar Disorders
- Schizophrenia & Psychosis
- Trauma & PTSD
- Women's & Perinatal Mental Health
- Psychotherapy
- Emergency Psychiatry
- Interventional Psychiatry & Neuromodulation
- Psychedelic Medicine
- Suicide Prevention
- OCD & Related Disorders
- Autism Spectrum
- Sleep Medicine
By location
- International
- Midwest US
- Northeast US
- Southern US
- Western US
- California (6)
- Chicago (5)
- Illinois (5)
- San Diego (5)
- Colorado (4)
- Florida (4)
- Denver (3)
- Louisiana (3)
- New Orleans (3)
- New Zealand (3)
- Reston (3)
- Texas (3)
- Virginia (3)
- Austin (2)
- Australia (2)
- Hawaii (2)
- New York (2)
- Orlando (2)
- Washington (2)
- Washington, D.C. (2)
- Adelaide (1)
- Albuquerque (1)
- Arizona (1)
- Asheville (1)
- Atlanta (1)
- Auckland (1)
- Bahamas (1)
- Baltimore (1)
- Barcelona (1)
- Boston (1)
- Brazil (1)
- Canada (1)
- Cape Town (1)
- Cartagena (1)
- Christchurch (1)
- Cincinnati (1)
- Colombia (1)
- Colorado Springs (1)
- Dallas (1)
- Florence (1)
- France (1)
- Georgia (1)
- Glasgow (1)
- Italy (1)
- Kapolei (1)
- Kentucky (1)
- Koloa (Kauai) (1)
- Lake Buena Vista (1)
- Las Vegas (1)
- Louisville (1)
- Lyon (1)
- Maryland (1)
- Massachusetts (1)
- Minneapolis (1)
- Minnesota (1)
- Montreal (1)
- Nashville (1)
- Nevada (1)
- New Mexico (1)
- North Carolina (1)
- Ohio (1)
- Paradise Island (1)
- Queenstown (1)
- Rio de Janeiro (1)
- San Francisco (1)
- Scottsdale (1)
- South Africa (1)
- Spain (1)
- Tennessee (1)
- Thredbo Village (1)
- United Kingdom (1)
By type
By audience
Speakers & topics
Recurring meetings
- All conference series
- AAAP Annual Meeting and Scientific Symposium
- AACAP Annual Meeting
- AADPRT Annual Meeting
- AAGP Annual Meeting
- AAPL Annual Meeting
- AAPP Annual Meeting
- AAS Annual Conference
- ACLP Annual Meeting
- ACNP Annual Meeting
- ADAA Annual Conference
- AGPA Connect
- AMERSA Annual National Conference
- ANPA Annual Meeting
- APA Annual Meeting
- APNA Annual Conference
- APNA Clinical Psychopharmacology Institute
- APSARD Annual Conference
- APsA National Meeting
- ASAM Annual Conference
- ASCP Annual Meeting
- ASKP3 Annual Conference
- Annual International Conference on ADHD
- Annual OCD Conference
- Best Practices for Mood Disorders
- CINP World Congress of Neuropsychopharmacology
- Child & Adolescent Psychopharmacology (MGH Psychiatry Academy)
- ECNP Congress
- European Congress of Psychiatry
- IEPA International Conference on Early Intervention in Mental Health
- INSAR Annual Meeting
- ISBD Annual Conference
- ISPN Annual Conference
- ISTSS Annual Meeting
- International Brain Stimulation Conference
- International Marcé Society Biennial Conference
- MGH Annual Conference on Psychedelics and Psychedelic Medicine
- MGH Annual Psychopharmacology Conference
- MasterPsych Child & Adolescent Psychiatry Conference
- MasterPsych Psychiatry Conference
- Mayo Clinic Psychiatry Clinical Updates
- Medical Psychiatry: Comprehensive Update Conference
- NEI Congress
- NPA National Psychopharmacology Update
- NPACE Napa: Mental Health & Women's Health Conference
- National Update on Behavioral Emergencies (NUBE)
- Postpartum Support International Annual Conference
- Psych Congress
- Psych Congress NP Institute
- Psychedelic Science
- RANZCP Congress
- RCPsych International Congress
- SBSM Annual Meeting (formerly American Psychosomatic Society Annual Meeting)
- SIRS Congress
- SLEEP Annual Meeting (APSS)
- SOBP Annual Meeting
- Substance Use Disorders: A Comprehensive Review and Update
- WFSBP World Congress of Biological Psychiatry
- World Congress of Psychiatry